{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:54:27Z","timestamp":1789656867871,"version":"4.0.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Cancer Center Support Grant\/Core","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K12 CA184746"],"award-info":[{"award-number":["K12 CA184746"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paul Calabresi Career Development Award for Clinical Oncology"},{"name":"MSK Parker Institute for Cancer Immunotherapy"},{"name":"Breakthrough Cancer\u2014Conquering KRAS for Pancreatic Cancer"},{"name":"Society of Immunotherapy for Cancer"},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed in 1%-2%. Several inhibitors of KRAS G12C have recently demonstrated promise in solid tumors, including pancreatic cancer. Little is known regarding clinical, genomics, and outcome data of this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with pancreatic cancer and KRAS G12Cmut were identified at Memorial Sloan Kettering Cancer Center and via the American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database. Clinical, treatment, genomic, and outcomes data were analyzed. A cohort of patients at Memorial Sloan Kettering Cancer Center with non-G12C KRAS pancreatic cancer was included for comparison.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 3571 patients with pancreatic ductal adenocarcinoma, 39 (1.1%) with KRAS G12Cmut were identified. Median age was 67\u2009years, and 56% were female. Median body mass index was 29.2\u2009kg\/m2, and 67% had a smoking history. Median overall survival was 13\u2009months (95% CI: 9.4 months, not reached) for stage IV and 26\u2009months (95% CI: 23 months, not reached) for stage I-III. Complete genomic data (via American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database) was available for 74 patients. Most common co-alterations included TP53 (73%), CDKN2A (33%), SMAD4 (28%), and ARID1A (21%). Compared with a large cohort (n\u2009=\u20092931) of non-G12C KRAS-mutated pancreatic ductal adenocarcinoma, ARID1A co-mutations were more frequent in KRAS G12Cmut (P\u2009&amp;lt;\u2009.05). Overall survival did not differ between KRAS G12Cmut and non-G12C KRAS pancreatic ductal adenocarcinoma. Germline pathogenic variants were identified in 17% of patients; 2 patients received KRAS G12C-directed therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pancreatic cancer and KRAS G12Cmut may be associated with a distinct clinical phenotype. Genomic features are similar to non-G12C KRAS-mutated pancreatic cancer, although enrichment of ARID1A co-mutations was observed. Targeting of KRAS G12C in pancreatic cancer provides a precedent for broader KRAS targeting in pancreatic cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djae095","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T03:13:36Z","timestamp":1714792416000},"page":"1429-1438","source":"Crossref","is-referenced-by-count":12,"title":["Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of <i>KRAS<\/i> G12C-mutated disease"],"prefix":"10.1093","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-2090","authenticated-orcid":false,"given":"Fergus","family":"Keane","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne F","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-350X","authenticated-orcid":false,"given":"Henry","family":"Walch","sequence":"additional","affiliation":[{"name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Singhal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Cowzer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Harrold","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El Dika","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiyinfolu","family":"Balogun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinela","family":"Capanu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[{"name":"Marie-Jos\u00e9e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5454","authenticated-orcid":false,"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY, USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"issue":"1","key":"2024090612013776700_djae095-B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2024090612013776700_djae095-B2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a seer-based study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"2024090612013776700_djae095-B3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.can-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"2024090612013776700_djae095-B4","author":"National Comprehensive Cancer Network","year":"2023"},{"issue":"27","key":"2024090612013776700_djae095-B5","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/jco.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024090612013776700_djae095-B6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"2024090612013776700_djae095-B7","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat Commun"},{"issue":"7592","key":"2024090612013776700_djae095-B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2024090612013776700_djae095-B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"Kras mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin Oncol"},{"key":"2024090612013776700_djae095-B10","doi-asserted-by":"publisher","first-page":"e2100245","DOI":"10.1200\/po.21.00245","article-title":"Landscape of krasg12c, associated genomic alterations, and interrelation with immuno-oncology biomarkers in kras-mutated cancers","volume":"6","author":"Salem","year":"2022","journal-title":"J Clin Oncol Precis Oncol"},{"issue":"7477","key":"2024090612013776700_djae095-B11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-ras(g12c) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"1","key":"2024090612013776700_djae095-B12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/nejmoa2208470","article-title":"Sotorasib in kras p.G12C\u2013mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"New Engl J Med"},{"issue":"25","key":"2024090612013776700_djae095-B13","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/jco.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a krasg12c mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024090612013776700_djae095-B14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-agent DIVARASIB (GDC-6036) in solid tumors with a kras G12C mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"New Engl J Med"},{"issue":"3","key":"2024090612013776700_djae095-B15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-impact)","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"1","key":"2024090612013776700_djae095-B16","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1038\/s41467-021-24109-5","article-title":"Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-access","volume":"12","author":"Rose Brannon","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"2024090612013776700_djae095-B17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.cd-17-0151","article-title":"AACR Project Genie: Powering Precision Medicine through an international consortium","volume":"7","author":"Andr\u00e9","year":"2017","journal-title":"Cancer Discov"},{"issue":"269","key":"2024090612013776700_djae095-B18","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative Analysis of Complex Cancer Genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"2024090612013776700_djae095-B19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.cd-12-0095","article-title":"The Cbio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"2024090612013776700_djae095-B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12920-017-0271-4","article-title":"Comprehensive detection of germline variants by MSK-impact, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing","volume":"10","author":"Cheng","year":"2017","journal-title":"BMC Med Genomics"},{"issue":"5","key":"2024090612013776700_djae095-B21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1042\/bst20180173","article-title":"Ras variant signalling","volume":"46","author":"Mo","year":"2018","journal-title":"Biochem Soc Trans"},{"issue":"9","key":"2024090612013776700_djae095-B22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"2024090612013776700_djae095-B23","doi-asserted-by":"crossref","first-page":"ND11","DOI":"10.1158\/1538-7445.AM2022-ND11","article-title":"Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers","volume":"82(suppl 12)","author":"Purkey","year":"2022","journal-title":"Cancer Res"},{"issue":"8","key":"2024090612013776700_djae095-B24","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/1078-0432.ccr-20-4023","article-title":"Treatment outcomes and clinical characteristics of patients with KRAS-G12C\u2013mutant non\u2013small cell lung cancer","volume":"27","author":"Arbour","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2024090612013776700_djae095-B25","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.ccr-11-3265","article-title":"Molecular epidemiology of egfr and kras mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related kras-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2024090612013776700_djae095-B26","doi-asserted-by":"publisher","first-page":"107293","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"Kras G12C in advanced NSCLC: Prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"issue":"18","key":"2024090612013776700_djae095-B27","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1158\/1078-0432.ccr-08-0646","article-title":"Frequency and distinctive spectrum of kras mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6312","key":"2024090612013776700_djae095-B28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"issue":"12","key":"2024090612013776700_djae095-B29","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1097\/jto.0000000000000687","article-title":"Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with Kras-mutant lung cancer","volume":"10","author":"Calles","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2024090612013776700_djae095-B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_360354","article-title":"Overcoming kras-mutant lung cancer","volume":"42","author":"Luo","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"2024090612013776700_djae095-B31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41591-020-0765-z","article-title":"Resistance looms for KRASG12C inhibitors","volume":"26","author":"Hata","year":"2020","journal-title":"Nat Med"},{"key":"2024090612013776700_djae095-B32","doi-asserted-by":"publisher","first-page":"e2300030","DOI":"10.1200\/po.23.00030","article-title":"Clinical and genomic features of response and toxicity to Sotorasib in a real-world cohort of patients with advanced KRAS g12c-mutant non\u2013small cell lung cancer","volume":"7","author":"Thummalapalli","year":"2023","journal-title":"J Clin Oncol Precis Oncol"},{"issue":"8","key":"2024090612013776700_djae095-B33","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel kras switch-II pocket mutation and polyclonal alterations converging on Ras\u2013MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"issue":"7886","key":"2024090612013776700_djae095-B34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"issue":"25","key":"2024090612013776700_djae095-B35","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/nejmoa2105281","article-title":"Acquired resistance to krasg12c inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"New Engl J Med"},{"issue":"1","key":"2024090612013776700_djae095-B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.cd-22-0405","article-title":"Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer","volume":"13","author":"Yaeger","year":"2022","journal-title":"Cancer Discovery"},{"issue":"7540","key":"2024090612013776700_djae095-B37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"1","key":"2024090612013776700_djae095-B38","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1038\/s41467-022-33172-5","article-title":"ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer","volume":"13","author":"Johnson","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2024090612013776700_djae095-B39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated kras G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"New Engl J Med"},{"issue":"8","key":"2024090612013776700_djae095-B40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to Krasg12c inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discovery"},{"issue":"7781","key":"2024090612013776700_djae095-B41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical kras(g12c) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2024090612013776700_djae095-B42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of kras-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discovery"},{"issue":"3","key":"2024090612013776700_djae095-B43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of SHP2 in the RAS\/mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cell Signal"},{"issue":"7","key":"2024090612013776700_djae095-B44","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to Krasg12c inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024090612013776700_djae095-B45","doi-asserted-by":"crossref","first-page":"TPS146","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS146","article-title":"Krystal-2: a phase I\/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation","volume":"39(suppl 3)","author":"Sabari","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024090612013776700_djae095-B46","doi-asserted-by":"publisher","first-page":"102287","DOI":"10.1016\/j.ctrv.2021.102287","article-title":"Targeting ARID1A mutations in cancer","volume":"100","author":"Mullen","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2024090612013776700_djae095-B47","doi-asserted-by":"publisher","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"2024090612013776700_djae095-B48","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat Med"},{"issue":"18","key":"2024090612013776700_djae095-B49","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with NAB-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New Engl J Med"},{"issue":"19","key":"2024090612013776700_djae095-B50","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox versus Gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New Engl J Med"},{"issue":"17","key":"2024090612013776700_djae095-B51","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1002\/cncr.33038","article-title":"Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma","volume":"126","author":"McIntyre","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"2024090612013776700_djae095-B52","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40261-017-0522-3","article-title":"Relationship between the expression of O6-methylguanine-DNA methyltransferase (MGMT) and p53, and the clinical response in metastatic pancreatic adenocarcinoma treated with FOLFIRINOX","volume":"37","author":"Vitellius","year":"2017","journal-title":"Clin Drug Invest"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae095\/57764869\/djae095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/9\/1429\/59032696\/djae095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/116\/9\/1429\/59032696\/djae095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T12:09:37Z","timestamp":1725624577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/116\/9\/1429\/7664169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae095","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,3]]}}}